NXTC NextCure Inc.

31.21
-1.99  -6%
Previous Close 33.2
Open 32
Price To Book 2.59
Market Cap 858,817,149
Shares 27,517,371
Volume 578,182
Short Ratio
Av. Daily Volume 228,734
Stock charts supplied by TradingView

NewsSee all news

  1. NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting

    BELTSVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  2. NextCure Reports First Quarter 2020 Financial Results

    BELTSVILLE, Md., May 07, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  3. NextCure to Present at BofA Securities Virtual Health Care Conference

    BELTSVILLE, Md., May 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  4. NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference

  5. NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors

    BELTSVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 biomarker data released at ASCO May 29, 2020. Combination clinical trial has been delayed due to COVID-19. Phase 2 data will be delayed.
NC318
Solid tumors
Phase 1 initiation delayed due to COVID-19.
NC410

Latest News

  1. NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting

    BELTSVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  2. NextCure Reports First Quarter 2020 Financial Results

    BELTSVILLE, Md., May 07, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  3. NextCure to Present at BofA Securities Virtual Health Care Conference

    BELTSVILLE, Md., May 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  4. NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference

  5. NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors

    BELTSVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  6. NextCure Reports Fourth Quarter and Full Year 2019 Financial Results

    BELTSVILLE, Md., March 12, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  7. NextCure to Present at the 40th Annual Cowen Health Care Conference

    BELTSVILLE, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  8. NextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference

    BELTSVILLE, Md., Feb. 18, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  9. NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BELTSVILLE, Md., Jan. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  10. NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference

    BELTSVILLE, Md., Nov. 26, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  11. NextCure Announces Closing of Public Offering

    BELTSVILLE, Md., Nov. 19, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  12. NextCure Announces Pricing of Public Offering of Common Stock

    BELTSVILLE, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  13. NextCure Announces Proposed Public Offering of Common Stock

    BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  14. NextCure Reports Third Quarter 2019 Financial Results

    BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  15. NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

    NC318 was well toleratedSingle agent activity observed in multiple tumor types, including a CR and a PR in NSCLCInitiated Phase 2 portion of the Phase 1/2 monotherapy trial and plans for a combo trial with standard of

  16. NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    BELTSVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing next-generation immunomedicines for cancer and other immune-related

  17. NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

    BELTSVILLE, Md., Oct. 02, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer

  18. NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC

    BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer